Company intelligence / Profile preview

908 Devices

Boston, Massachusetts, United States908devices.com ↗

Ownership: Public · MASS
Development stage: Commercial

Overview

Company has commercialized several handheld and desktop chemical analysis devices widely adopted in law enforcement, bioprocessing/pharma R&D labs. In Q4/FY2024 revenue grew by double digits year-over-year. Recently divested its bioprocessing desktop portfolio to focus on handheld markets addressing health/safety crises such as opioid detection. No clinical results as the company does not develop drugs.

Modalities: Device
Industry: Drug Discovery Services

Partnerships

Advanced Mammalian Biomanufacturing Innovation Center (AMBIC) academic-industry consortium partnership for biotherapeutic manufacturing innovation.GSK uses multiple REBEL analyzers from the former desktop product line.

Financials

Market cap: $402.5M
Total revenue: $16.1M
Enterprise value: $305.2M

Beyond the preview

Go deeper on 908 Devices.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 908 Devices.

Explore the full profile